Tenet Healthcare (THC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Executive summary
Annual meeting scheduled for May 27, 2026, to be held virtually for shareholders of record as of April 2, 2026.
Proxy materials, including the Notice of Annual Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request.
Voting matters and shareholder proposals
Shareholders will vote on the election of 12 director nominees.
Advisory vote on executive compensation is included as Proposal 2.
Ratification of Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026, is Proposal 3.
Board recommends voting FOR all director nominees and FOR Proposals 2 and 3.
Board of directors and corporate governance
Twelve director nominees are listed for election, including Saumya Sutaria, J. Robert Kerrey, Vineeta Agarwala, and others.
Latest events from Tenet Healthcare
- 2025 performance exceeded targets, supporting high executive pay and strong shareholder returns.THC
Proxy filing16 Apr 2026 - Q4 2025 saw double-digit EBITDA and EPS growth, with a strong 2026 outlook and major transactions.THC
Q4 202513 Apr 2026 - AI-driven efficiencies and targeted investments fuel growth in high-acuity care and ambulatory services.THC
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Q2 2024 net income and EBITDA surged, with FY 2024 outlook and buybacks increased.THC
Q2 20243 Feb 2026 - $2.65B deal regains full control, secures $1.9B payments, and enables tech-driven growth.THC
Status update2 Feb 2026 - Deleveraging and disciplined growth drive strong performance in hospitals and ambulatory services.THC
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q3 net income soared to $472M, guidance raised, and Ambulatory Care led robust growth.THC
Q3 202418 Jan 2026 - Operational improvements, strong demand, and portfolio optimization drive growth outlook.THC
UBS Global Healthcare Conference14 Jan 2026 - Q4 and FY 2024 delivered margin growth, deleveraging, and strong ambulatory expansion.THC
Q4 20248 Jan 2026